These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1693138)

  • 1. Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog.
    Newman RA; Siddik ZH; Travis EL; Followill D; Ayele W; Burditt T; Krakoff IH
    Invest New Drugs; 1990 Feb; 8(1):33-41. PubMed ID: 1693138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells.
    Tueni EA; Newman RA; Baker FL; Ajani JA; Fan D; Spitzer G
    Cancer Res; 1989 Mar; 49(5):1099-102. PubMed ID: 2465080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleomycin pulmonary toxicity: current status and future directions.
    Comis RL
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):64-70. PubMed ID: 1384147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrogenic structure-activity study of the bleomycin molecule.
    Newman RA; Hacker MP; Sakai TT
    Toxicol Appl Pharmacol; 1983 Sep; 70(3):373-81. PubMed ID: 6195769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial.
    Yoshida T; Ogawa M; Ota K; Yoshida Y; Wakui A; Oguro M; Ariyoshi Y; Hirano M; Kimura I; Matsuda T
    Cancer Chemother Pharmacol; 1993; 31(6):445-8. PubMed ID: 7680966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tallysomycin S10b: experimental antitumor activity and toxicity.
    Schurig JE; Rose WC; Hirth RS; Schlein A; Huftalen JB; Florczyk AP; Bradner WT
    Cancer Chemother Pharmacol; 1984; 13(3):164-70. PubMed ID: 6207948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology.
    Sikic BI; Young DM; Mimnaugh EG; Gram TE
    Cancer Res; 1978 Mar; 38(3):787-92. PubMed ID: 75060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleomycin injury of the lung in a mast-cell-deficient model.
    O'Brien-Ladner AR; Wesselius LJ; Stechschulte DJ
    Agents Actions; 1993 May; 39(1-2):20-4. PubMed ID: 7506864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin.
    Oury TD; Thakker K; Menache M; Chang LY; Crapo JD; Day BJ
    Am J Respir Cell Mol Biol; 2001 Aug; 25(2):164-9. PubMed ID: 11509325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.
    Failla M; Genovese T; Mazzon E; Gili E; Muià C; Sortino M; Crimi N; Caputi AP; Cuzzocrea S; Vancheri C
    Respir Res; 2006 Nov; 7(1):137. PubMed ID: 17118201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.
    Corboz MR; Zhang J; LaSala D; DiPetrillo K; Li Z; Malinin V; Brower J; Kuehl PJ; Barrett TE; Perkins WR; Chapman RW
    Pulm Pharmacol Ther; 2018 Apr; 49():95-103. PubMed ID: 29408757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury.
    Smith RE; Strieter RM; Phan SH; Lukacs NW; Huffnagle GB; Wilke CA; Burdick MD; Lincoln P; Evanoff H; Kunkel SL
    J Immunol; 1994 Nov; 153(10):4704-12. PubMed ID: 7525712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic behavior of [57Co]bleomycin liposomes in mice: comparison with the unencapsulated substance.
    Fichtner I; Arndt D; Reszka R; Gens J
    Anticancer Drugs; 1991 Dec; 2(6):555-63. PubMed ID: 1725271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary toxicity studies of bleomycin and talisomycin.
    Schlein A; Schurig JE; Baca C; Bradner WT; Crooks ST
    Cancer Treat Rep; 1981; 65(3-4):291-7. PubMed ID: 6165468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic index of bleomycin when administered by continuous infusion in mice.
    Sikic BI; Collins JM; Mimnaugh EG; Gram TE
    Cancer Treat Rep; 1978 Dec; 62(12):2011-7. PubMed ID: 87269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratracheal versus intravenous administration of bleomycin in mice: acute effects.
    Lindenschmidt RC; Tryka AF; Godfrey GA; Frome EL; Witschi H
    Toxicol Appl Pharmacol; 1986 Aug; 85(1):69-77. PubMed ID: 2425458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleomycin and radiation-induced lung damage in mice.
    Collis CH; Down JD; Pearson AE; Steel GG
    Br J Radiol; 1983 Jan; 56(661):21-6. PubMed ID: 6185171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.